MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients

Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male Patients After Switch to Atazanavir/Ritonavir

(2016) Anthony J. Busti et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less

(2013) Jean-Michel Molina et al.   AIDS

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

(2013) Antonella d’Arminio Monforte et al.   AIDS

Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

(2013) Sabrina Cipriani et al.   CIRCULATION

Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues

(2013) G. Guaraldi et al.   HIV CLINICAL TRIALS

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS

(2013) E. Arathoon et al.   INTERNATIONAL JOURNAL OF STD & AIDS

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy

(2013) B. Taiwo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy

(2013) Erika F. Silva et al.   JOURNAL OF INFECTIOUS DISEASES

Combination Antiretroviral Therapy With Raltegravir Leads to Rapid Immunologic Reconstitution in Treatment-Naive Patients With Chronic HIV Infection

(2013) S. Pallikkuth et al.   JOURNAL OF INFECTIOUS DISEASES

Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women

(2013) Kathleen V. Fitch et al.   JOURNAL OF INFECTIOUS DISEASES

Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

(2013) Claudio Ucciferri et al.   JOURNAL OF MEDICAL VIROLOGY

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

(2013)   LANCET

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

(2012) Grace A. McComsey et al.   AIDS

Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens

(2012) Alba Bigoloni et al.   AIDS

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

(2012) Esteban Martínez et al.   AIDS

A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy

(2012) Jordan E. Lake et al.   AIDS PATIENT CARE AND STDS

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Effects of Rilpivirine on Human Adipocyte Differentiation, Gene Expression, and Release of Adipokines and Cytokines

(2012) Julieta Díaz-Delfín et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz

(2012) Leysa J. Gomez-Sucerquia et al.   ANTIVIRAL RESEARCH

Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen

(2012) Emily Huesgen et al.   ANTIVIRAL THERAPY

A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity

(2012) Graeme J Moyle et al.   ANTIVIRAL THERAPY

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

(2012) Maria Saumoy et al.   ATHEROSCLEROSIS

Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir

(2012) Daria Gotti et al.   HIV CLINICAL TRIALS

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

(2012) Michael J. Kozal et al.   HIV CLINICAL TRIALS

Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy

(2012) CO Hileman et al.   HIV MEDICINE

A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection

(2012) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection

(2012) Eduardo Gotuzzo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals

(2012) Supriya Krishnan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study

(2012) M. Masia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF–Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202

(2012) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks

(2011) Judith S. Currier et al.   AIDS PATIENT CARE AND STDS

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

(2011) Josep M Llibre et al.   ANTIVIRAL THERAPY

Autophagy as a rescue mechanism in Efavirenz-induced mitochondrial dysfunction: A lesson from hepatic cells

(2011) Nadezda Apostolova et al.   Autophagy

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

(2011) Jürgen K. Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

(2011) A. MacInnes et al.   HIV CLINICAL TRIALS

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

(2011) D Podzamczer et al.   HIV MEDICINE

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

(2011) SME Vrouenraets et al.   HIV MEDICINE

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Impact of atazanavir-based HAART regimen on the carotid intima–media thickness of HIV-infected persons: a comparative prospective cohort

(2010) Luc de Saint-Martin et al.   AIDS

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

(2010) Robert L Murphy et al.   AIDS

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults

(2010) Elena Ferrer et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial

(2010) Benjamin Young et al.   HIV CLINICAL TRIALS

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients

(2009) Takara L Stanley et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Efficacy and Safety of Atazanavir-Ritonavir Plus Abacavir-Lamivudine or Tenofovir-Emtricitabine in Patients with Hyperlipidaemia Switched from a Stable Protease Inhibitor-Based Regimen Including One Thymidine Analogue

(2009) Leonardo Calza et al.   AIDS PATIENT CARE AND STDS

Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study

(2009) Grace McComsey et al.   CLINICAL INFECTIOUS DISEASES

Baseline Lipid Levels Rather Than the Presence of Reported Body Shape Changes Determine the Degree of Improvement in Lipid Levels After Switching to Atazanavir

(2009) M.G.A. van Vonderen et al.   HIV CLINICAL TRIALS

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

(2009) Josep Mallolas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir

(2009) Michael Sension et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

(2009) Signe Westring Worm et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

(2009) Princy N Kumar et al.   AIDS Research and Therapy

Chemokines and Cardiovascular Risk

(2008) Pål Aukrust et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial

(2008) A J Flammer et al.   HEART

Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen

(2008) M Colafigli et al.   HIV MEDICINE

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Common CCR5-del32 Frameshift Mutation Associated With Serum Levels of Inflammatory Markers and Cardiovascular Disease Risk in the Bruneck Population

(2008) Ali R. Afzal et al.   STROKE